AKTX Earnings & Financial Statements
Akari Therapeutics, Plc
$8.84
+$1.56(+21.43%)
43
Overall
60
Value
40
Tech
31
Quality
Market Cap
$16.64M
Volume
55.69K
52W Range
$3.02 - $39.64
Target Price
$25.50
AKTX earnings and financial statements: Akari Therapeutics, Plc's income statement, balance sheet and cash flow statement, annual and quarterly.
AKTX Annual Financial Statements
| Fiscal year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating income | -$21.64M | -$16.81M | -$23.09M | -$17.21M | -$17.98M |
| EBITDA | -$23.69M | -$9.24M | -$17.74M | -$17.42M | -$17.32M |
| Net income | -$19.79M | -$10.01M | -$17.75M | -$17.42M | -$17.08M |
| EPS (diluted) | - | $-2.05 | - | - | $-400.00 |
| Fiscal year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total assets | $50.56M | $4.36M | $13.83M | $11.65M | $14.60M |
| Total liabilities | $28.33M | $4.58M | $12.04M | $6.09M | $5.22M |
| Shareholders’ equity | $22.23M | -$229.0K | $1.79M | $5.55M | $9.38M |
| Cash and equivalents | $2.60M | $3.85M | $13.25M | $9.36M | $14.06M |
| Long-term debt | $700.0K | - | - | - | - |
| Fiscal year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating cash flow | -$12.55M | -$16.43M | -$21.50M | -$18.85M | -$16.95M |
| Free cash flow | -$12.55M | -$16.43M | -$21.50M | -$18.85M | -$16.95M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AKTX | $8.84 | +21.4% | 55.69K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |